Higher expression of PAR-1 may be associated with severity of Glioblastomas

Sukanya Tripathy  
University of Lucknow Faculty of Science

Sanjay Singh  
Babasaheb Bhimrao Ambedkar University School of Bio-Science and Bio-Technology

Sarfaraj Ahmad Siddiqui  
Babasaheb Bhimrao Ambedkar University School of Bio-Science and Bio-Technology

Atul Rawat  
Babasaheb Bhimrao Ambedkar University School of Bio-Science and Bio-Technology

Dinesh Raj Modi  
Babasaheb Bhimrao Ambedkar University School of Information Science and Technology

Monisha Banerjee  
University of Lucknow Faculty of Science

R C Sobti  
Panjab University

Anand Prakash (✉ anandprakash@mgcub.ac.in)  
MGCUB: Mahatma Gandhi Central University  https://orcid.org/0000-0002-7676-7836

Research Article

Keywords: Glioblastoma multiforme, Protease activated receptors (PARs), Migration, Invasion, PAR-1 activator (TFLLR), PAR-1 inhibitor (SCH-79797)

DOI: https://doi.org/10.21203/rs.3.rs-270158/v1

License: ☕️ ☀️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Glioblastoma multiforme (GBM) is one of the most malignant types of central nervous system tumors. Protease-activated receptor 1 (PAR1) is a G protein-coupled receptor that elicits several pro-tumoral responses. It has been linked to proliferation and invasiveness in glioblastomas. In the present study, prevalence of the receptor (PAR-1) and its associated downstream signaling was studied in two human glioblastoma cell lines D-54 MG and U-87 MG. The expression of PAR1 was found to be significantly higher in D-54 MG cell-line when compared to U-87 MG cell-line. The activation of PAR-1 in the presence of TFLLR (a synthetic peptide activator of PAR-1) led to an increase in ERK ½ activity along with a significant increase in the migration and invasion of these cell-lines. Subsequent treatment with SCH-79797 (PAR-1 inhibitor) significantly decreased the migration and invasion in these glioma cell lines, respectively. The relative increase and decrease in the migration and invasion of these cell lines in presence of activator and inhibitor respectively was found to be linked with the expression of PAR-1. To conclude the study links the PAR-1 signaling with progression of Glioblastoma. PAR-1 and associated downstream signaling may be a potential therapeutic target to preclude the pathogenesis of gliomas.

Introduction

Gliomas are primary malignant brain tumors classified as astrocytomas, glioblastomas, oligodendrogliomas, ependymomas and mixed gliomas according to their origin [1–5]. They are amongst one of the highly invasive malignant brain tumors with a global burden of 2–3 new cases per 100,000 people per year worldwide [6]. Due to its aggressive behavior the median survival time for a recently diagnosed patient is approximately 1 year, with < 5% of patients surviving 5 years post-diagnosis [7, 8]. Once diagnosed, patients undergo surgical removal by adjuvant radiotherapy and chemotherapy [9, 10]. Tumor resists radiotherapy as well as its invasive ability [11] resulting in lower survival [12]. Recent data shows tumor incidence in India, to be 5 to 10 per 100,000 populations and 2% malignancy [13, 14]. Of these astrocytomas (38.7%) occur most frequently and the majority of the patients diagnosed have grade IV gliomas (60%) [15, 16]. In a study performed by Tao Sun [17], the frequency of tumor occurrence was found to be higher in males although with higher malignancy in females.

Till date many molecular targets have been screened for the early detection of gliomas and of these protease-activated receptor-1 (PAR-1) is a potential candidate. Several studies indicate that PARs play an important role in the progression of prostate cancer [18, 19], breast cancer [20] and lung cancer [21, 22]. Recently the expression of PAR-1 has been shown to play a pivotal role in migration, invasion, and angiogenesis of gliomas.

PARs are thrombin based receptors and among four types, activation of PAR-1, 3 and 4 occur by thrombin whereas PAR-2 activation takes place by trypsin-like serine proteases. Proteases bind to the extracellular domain of N-terminus at specific sites and expose the new N-terminal associated ligand thus activating the cleaved receptor [23, 24]. Expression of the thrombin based PAR-1 has a key role in the metastatic
behavior of many types of cancer. Human melanoma cells expressing PAR-1 have enhanced metastatic potential [25, 26] with upregulation $G_{aq}$ and associated ERK1/2 signaling [27].

The present study examined the expression of PAR-1 in two different glioma cell lines i.e., D-54 MG (female cell line) and U-87 MG (male cell line). The PAR-1 signaling via ERK ½ and its effect on the migration and invasion in these gliomas cell-lines was analyzed. The effect of PAR-1 activator and inhibitor confirms the role of these receptors in pathogenesis of gliomas.

**Methods**

**Cell culture**

Glioma cells D-54 MG (RRID:CVCL_5735) were purchased from Thermo Fisher Scientific and U-87 MG (RRID:CVCL_GP63) were purchased from NCCS, Pune. DMEM medium was used to culture the cells containing 10% fetal bovine serum, 2 mM glutamine, 200 penicillin/ml, and 0.2 g/ml streptomycin and incubated at 37 °C in a controlled humid atmosphere with 5% CO2. The cells were counted using a trypan blue exclusion method by hemocytometer.

**m-RNA expression of PAR-1 and RT-PCR**

Total RNA was obtained from D-54 MG and U-87 MG cells lines with Purelink RNA mini kit from invitrogen (Carlsbad, CA). 1 µg of RNA was reverse-transcribed using GeneAmp RT kit (Applied biosystems). Following primers were used; forward 5′ CCTATGAGACAGCCAGAATC 3′ and reverse 5′ GCTTCTTGACCTTCATCC 3′ for PAR-1 Glyceraldehyde phosphate dehydrogenase (GAPDH) was used as a control with forward 5′ TTCAACGGCACAGTCAAGGC 3′ and reverse 5′ TCCACCACCTGTTGCTGTAGC 3′ primers respectively (Oikawa et al. 2013). PCR cycles were executed and the denaturation occurs at 95 °C for 15 min; then at 94 °C for 60 s, annealing temperature was 51 °C (GAPDH), 55 °C (PAR-1) for 90 s, and 72 °C for extension 30 s for 35 cycles; lastly the additional extension at 72 °C for 10 min.

**PAR-1 protein expression and Western Blotting**

Serum deprived confluent cells were taken for treatment and for subsequent western blot analysis. The cells were trypsinized and centrifuged at 500g for 5 minutes. Monolayer was rinsed with the chilled phosphate-buffered saline (PBS 0.1M) and a cytoplasmic fraction was obtained (Nuclear-cytoplasmic extraction kit, G-Biosciences Cat.786-182). The lysate was mixed on a rocker at 4°C for 15 min followed by centrifugation at 14,000 g in a pre-cooled centrifuge (Eppendorf Ultracentrifuge 5810R) for 15 min. at 4°C, the supernatant containing protein was transferred to a fresh and sterile 1.5 ml centrifuge tube, and the pellet was discarded. The concentration of collected protein was determined by the Bradford Reagent using bovine serum albumin (BSA) as standard. 10% SDS-polyacrylamide gel electrophoresis was performed with 10 µg protein/lane and then transferred to Polyvinylidene fluoride (PVDF) membrane. Blocking was performed with 5% skimmed milk for 3h at 4°C followed by three washing in 0.1M PBST (PBS with 0.1% Tween-20). Membrane was incubated overnight at 4°C with specific antibodies against
PAR-1 [Anti-PAR-1] (Abcam cat., ab114346). Next day after three repeated washing, peroxidase conjugated anti-mouse or anti-rabbit IgG (1:1500, Abcam cat. (ab150157) secondary antibody was added to membranes for 2h at room temperature. After washing the membrane protein bands were imaged by enhanced chemiluminescence (ECL) substrate (Pierce™ ECL Western Blotting Substrate Cat No. 32109). The quantification of protein was performed through densitometric digital analysis of protein bands using Image J software. β-actin was used to normalize bands of PAR-1.

Expression of p-ERK by Western Blotting

Serum deprived confluent cells were taken for treatment and western blot analysis. The cells were trypsinized and centrifuged at 500g for 5 minutes. The monolayer was rinsed with the chilled phosphate-buffered saline (PBS 0.1M) and a cytoplasmic fraction was obtained (Nuclear-cytoplasmic extraction kit, G-Biosciences Cat.786-182). The lysate was mixed on a rocker at 4°C for 15 min followed by centrifugation at 14,000 g in a pre-cooled centrifuge (Eppendorf cooling centrifuge 5810R) for 15 min. at 4°C, the supernatant containing protein was transferred to a fresh and sterile 1.5 ml centrifuge tube, and the pellet was discarded. The concentration of collected protein was determined by the Bradford Reagent using bovine serum albumin (BSA) as standard. 10% SDS-polyacrylamide gel electrophoresis was performed with 25 μg protein/lane and then transferred to Polyvinylidene fluoride (PVDF) membrane. Blocking was performed with 5% skimmed milk for 3h at 4°C followed by three washing in 0.1M PBST (PBS with 0.1% Tween-20). Membranes were allowed to incubate overnight at 4°C with specific antibodies against ERK1/2 [p44/42 MAPK (1:2,000)] (Abcam, ab17942). Next day after three repeated washing, peroxidase conjugated anti-mouse or anti-rabbit IgG (1:1000, Abcam cat. (ab150157) secondary antibody was added to the membrane for 2h at room temperature. After washing the membrane protein bands were imaged by enhanced chemiluminescence (ECL) substrate (Pierce™ ECL Western Blotting Substrate Cat No. 32109). The quantification of protein was performed through densitometric digital analysis of protein bands using Image J software. Untreated cells were taken as control to compare with the cell-line.

Transwell Migration Assay

Transwell filter chambers of 8μm polycarbonate with 6mm inserts (Costar Corporation, Cambridge, MA) were used for migration assay. Recently subcultured, semi confluent D-54 MG and U-87 MG glioma cells, serum starved for 12 hours were harvested with EDTA (1.5 mM) and consecutively washed with phosphate buffer saline (PBS), and resuspended in DMEM at 2*10^6 cells/ml. 200μl cell aliquot was placed on the upper filter surface. SCH-79797 in DMEM was mixed to the upper chamber (with cells) and the lower chamber had 600μL DMEM with FBS. Filters were again kept at 37°C and 95% O2 and 5% CO2 for 5 hr. The upper surface cells were scraped off and lower surface cells were fixed with 4% paraformaldehyde (PFA) for 5 min. The obtained lower surface cells were stained with 1% crystal violet in 0.2 M sodium borate buffer at pH 9.0.

Matrigel Invasion Assay
Subcultured, semi confluent serum starved for 12 hours cells were harvested and resuspended in DMEM at 200,000 cells/ml. 250 µl of the cell aliquot was loaded in each matrigel coated chamber and then incubated at 37°C, 5% CO2 for 12 hr. Filters were then returned to the incubator for 5 hr. The upper surface cells were scraped off and lower surface cells were fixed with 4% paraformaldehyde (PFA) for 5 min. The obtained lower surface cells were stained with 1% crystal violet in 0.2 M sodium borate buffer at pH 9.0. Untreated cells were taken as control.

**Statistical analysis**

Statistical analyses were performed using GraphPad Prism version 8 (GraphPad Software). The results were presented as mean ± standard error mean (±SEM). Differences between the means were analyzed using independent t-test and One-way ANOVA. All the statistical analysis was performed at the significance level of p< 0.05.

**Results**

**m-RNA expression of PAR-1 receptor**

PAR-1 expression was assessed in D-54 MG and U-87 MG cell lines using RT-PCR. As evident, the D-54 MG cell-line has relatively higher mRNA expression than U-87 MG cell line [p<0.001; F (2, 12) =47.60] (Figure 1). The expression was analyzed by the Densitometric analysis of the bands using Image Studio Lite Ver 5.2.

**Protein expression of PAR-1 receptor**

To further validate the m-RNA expression obtained for the PAR-1 receptor in cell-lines the protein expression for the same was performed. Similar results were obtained by the Western blot analysis also. The receptor was expressed more in D-54 MG cell-line than U-87 MG cell-line [p<0.001; F (2, 12) =50.60] (Figure 2). The intensity of the bands was analyzed by Densitometric analysis using Image Studio Lite Ver 5.2.

**p-ERK a functional representative of PAR-1 activation**

ERK1/2 signaling has been reportedly linked with the PAR-1 downstream signaling and has been correlated with the pathogenesis of gliomas. To analyze the effect of PAR-1 activation in D-54 MG and U-87 MG cell-lines the cells were treated with 30 µM TFLLR (PAR-1 activator) and protein was extracted at different time points for western blot. Untreated cells were taken as control. The persistent activation of p-ERK¹⁄₂ was found in the D-54 MG cell-line [p<0.001; F (6, 28) =834.0] but not in the U-87 MG cell-line [p<0.01; F (6, 28) =2059.0] where the activation of p-ERK¹⁄₂ considerably decreased (Figure 3a). p-ERK½ in D-54 cell line upregulation after 30 min also but in U-87 MG cell-line the signal intensity was persistently low after 30 min. (Figure 3b). Thus the results suggest that the ERK ½ is activated through its enhanced phosphorylation by the PAR-1 activation and it plays a role in pathogenesis of gliomas.
Migration of D-54 MG and U-87 MG cells by PAR-1 activation

Effect of PAR-1 in migration of both the cell-lines of glioblastoma was observed by transwell migration assay. TFLLR (30 µM) activator sequence of PAR-1 was applied to the upper chamber of the transwell. TFLLR increased the migration in D-54 MG cell line \( t = 7.390, p<0.001 \) (Figure 4a) but no significant change in the migration of U-87 MG cell line \( t = 1.697, p>0.05 \) as analyzed by t-test (Figure 4b).

To confirm the role of PAR-1 in migration, we tested the effect of inhibitor SCH-79797 on TFLLR based migration. As seen in Figure 5a, PAR1 inhibitor SCH-79797 (3 µM) inhibited TFLLR-induced migration in D-54 MG cell-line \[ F (2, 12) = 60.07, p<0.001 \] further suggesting that PAR1 is involved in the migration of D-54 MG cell-line. Similarly, the decrease in the migration of U-87 MG cell-line was observed when equated with the TFLLR induced cells \[ F (2, 12) = 23.52, p<0.001 \] (Figure 5b).

**PAR-1 activation enhances invasion in Matrigel invasion assay**

To further corroborate the PAR-1 activation and invasion by its agonist we treated the cell-lines with thrombin, an endogenous ligand of PAR-1. The effective concentration \( (EC_{50}) \) of thrombin in D-54 MG and U-87 MG cell-line was observed first. It was found that D-54 MG cells show activation at lower concentrations of thrombin (0.1U/ml) but U-87 MG shows PAR-1 activation only at higher concentrations (1U/ml) (Figure 6). Then the effect of thrombin on invasion was studied. It was found that the thrombin significantly increased the invasion of D-54 MG cell-line \[ F (2, 12) = 98.72, p<0.0001 \] (Figure 7a) but not in U-87 MG cell-line \[ F (2, 12) = 9.894, p>0.05 \] (Figure 7b).

We further analyzed the effect of the PAR-1 inhibitor SCH-79797 on TFLLR induced invasion of cells. SCH-79797 significantly decreased the invasion in both D-54 MG cell-line \[ F (2, 12) = 98.72, p<0.0001 \] (Figure 8a) and U-87 MG cells \[ F (2, 12) = 9.894, p>0.01 \] (Figure 8b). However the decrease in the invasion across the matrigel in case of D-54 MG cell-line was highly significant as compared to U-87 MG cell-line.

**Discussion**

Glioblastoma is one of the most malignant tumors among all other astrocytomas and pathogenicity of these cells is the chief problem associated with the cure. Many studies performed earlier have reported PAR-1 in facilitating progression and severity of gliomas [28]. The present study was performed to find an association between prevalence of PAR-1 and its impact on pathogenesis of the glioblastoma. Two cell lines of glioblastoma were gauged for expression of PAR-1 receptor followed by pharmacologic intervention to look at the involvement of this receptor in invasiveness of these cell lines and the signaling involved.

Our first aim was to find out if the cell lines being used in the study had differential expression of PAR-1 mRNA. The reverse transcription of total mRNA revealed a difference in the expression pattern of the PAR-1 in the two cell lines with significantly higher expression of PAR-1 in the D-54 MG cell line than the U-87 MG cell line. Earlier studies have shown a positive correlation between the PAR-1 receptor m-RNA
expression and expression of PAR receptors on the cell surface [29]. Further many studies have found an association between higher expression of these receptors to greater malignancy [30].

We then asked whether activation of these receptors influence the ERK ½ dependent signaling pathway which is associated with cellular proliferation, migration and invasion in these cell-lines or not. In earlier studies the ERK½ signaling has been linked with PAR-1 downstream signaling and has been correlated with the pathogenesis of gliomas [31, 32]. Activation of PAR-1 has been shown to induce proliferation in astrocytes via MAPK involving distinct signaling pathways [33]. Activation of PAR-1 by a synthetic peptide PAR-1 activator TFLLR led to an increased level of phospho ERK ½ in both D-54 MG and U-87 MG cells. However in D-54 MG cell-lines there was a persistent increased expression of p-ERK ½ as compared to U-87 MG cell-line in which it subsided after 30 minutes and this may be because of differential signaling resulting from differential expression of PAR-1 in these cell lines. This result corroborated with the increased expression of PAR-1 in D-54 MG cell-line in contrast to U-87 MG cell-line.

A number of studies in the last decade point towards significant involvement of PAR-1 and its ligand thrombin in the progression of glioma [34–38]. Thrombin is an endogenous ligand for the PAR-1 receptor [28]. By activating the receptor it induces glioma growth and proliferation [39]. Overall the activation of PAR-1 via thrombin increases the likelihood of neuro-glial transmission, amplification of cellular signaling, inflammation, differentiation, proliferation, malignancy of glial cells, and tumor related brain edema [40, 41]. In the present study a concentration-dependent increase was observed in the migration of D-54 MG cells but not in the migration of U-87 MG cells. In U-87 MG cells the migration increased only at a higher concentration (10 U/ml). These observations further add to the role of PAR-1 in migration of glioma cells.

Next we looked for an association between the prevalence of PAR-1 receptor gene expression and migration and invasion in these cell-lines. It was found that the migration and invasion of D-54 MG cells increases in a concentration-dependent manner as opposed to that of U-87 MG cells which increased only at a higher concentration. The higher expression of PAR-1 in D-54 than U-87 cells in this study points towards an association between the PAR-1 signaling and pathogenicity. This is in line with previous studies where the prevalence of PAR-1 receptors has been shown to be associated with the pathogenesis of some glioblastoma cell lines [42]. Some later studies have also correlated angiogenesis with over-expression of PAR-1 in Glioblastoma multiforme [43].

The TFLLR induced migration and invasion in the D-54 MG cell lines was significantly higher as compared to the U-87 MG cell lines. This could be because of the over-expression of PAR-1 receptors in the D-54 MG as compared to the U-87 MG. The involvement of PAR-1 was further confirmed by use of a specific inhibitor SCH-79797. It was observed that use of specific inhibitor SCH-79797 significantly reduced the TFLLR induced increase in the migration and invasion of D-54 MG. Our results are in line with many previous studies both in rodents and human tissues that have reported active involvement of PAR-1 receptors in the progression of Glioblastoma multiforme [44]. These results along with ours suggest an association between PAR-1 expression and glioma migration. Earlier studies have found that activated
PAR-1 fails to be down-regulated in carcinomas [45] by persistently activating ERK1/2 and thus inducing cellular pathogenesis.

There are certain reports [46] which have correlated gender with incidence and survival of gliomas. The incidence of gliomas is less in women, but once it occurs it progresses more rapidly than in males. The two different human origin glioma cell lines i.e., the D-54 MG and U-87 MG used in this study are coincidentally of female origin and male origin respectively. This again provides a weightage to the findings in the present study where the rate of migration and invasion in D-54 MG cells is higher than U-87 MG cells and this may be an explanation for higher aggressiveness of D-54 MG because of the increased expression of PAR-1 as compared to U-87 MG.

**Conclusion**

It was found that activation of PAR-1 and its inhibition causes the increased and decreased glioma migration and invasion respectively and also had a differential effect on the associated downstream ERK signaling. These results indicate that PAR-1 and the downstream signaling have critical roles in progression of gliomas and may serve as potential drug targets for controlling and treating Glioblastoma multiforme. Thus, PARs can provide an alternative to the conventional radio chemotherapy and might help in the survival of GBM patients.

**Declarations**

**Funding**

The financial assistance for the work was provided by Rajiv Gandhi Centre for Biotechnology (RGCB), DBT, Thiruvananthapuram, Kerala, India (BT/2/2015-IFD).

**Conflict of Interest**

The authors declare that they have no conflict of interest.

**Availability of Data and Material**

The data supporting the results of the present study are provided by the corresponding author.

**Author Contributions**

ST and SS performed the experiments, SAS and AR helped in manuscript preparation, DRM, RCS and MB provided the consumables and space to work. The core idea was generated by AP.

**References**
1. Holland EC (2000) Glioblastoma multiforme: The terminator. Proc Natl Acad Sci U S A 97:6242–6244. doi:10.1073/pnas.97.12.6242
2. Maher EA, Furnari FB, Bachoo RM et al (2001) Malignant glioma: Genetics and biology of a grave matter. Genes Dev 15:1311–1333. doi:10.1101/gad.891601
3. Schwartzbaum JA, Fisher JL, Aldape KD et al (2006) Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2:494–503. doi:10.1038/ncpneuro0289
4. Agnihotri S, Burrell KE, Wolf A et al (2013) Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp (Warsz) 61:25–41. doi:10.1007/s00005-012-0203-0
5. Hanif F, Muzaffar K, Perveen K et al (2017) Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pacific J Cancer Prev 18:3–9. doi:10.22034/APJCP.2017.18.1.3
6. ICBTRotUS H (2012) Central brain tumor registry of the United States statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2004–2008. Neuro Oncol 14(Suppl. 5):v1–v49. 10.1093/neuonc/nos218
7. Aldape KD, Okcu MF, Bondy ML et al (2003) Molecular Epidemiology of Glioblastoma. Cancer J 9:99–106. doi:10.1097/00130404-200303000-00005
8. Reuss D, Von Deimling A (2009) Hereditary tumor syndromes and gliomas. Recent Results Cancer Res 171:83–102. doi:10.1007/978-3-540-31206-2_5
9. Ryu S, Buatti JM, Morris A et al (2014) The role of radiotherapy in the management of progressive glioblastoma: A systematic review and evidence-based clinical practice guideline. J Neurooncol 118:489–499. doi:10.1007/s11060-013-1377-6
10. Huang J, Samson P, Perkins SM et al (2017) Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base. J Neurooncol 131:593–601. doi:10.1007/s11060-016-2331-6
11. Lee SY (2016) Temozolomide resistance in glioblastoma multiforme. Genes Dis 3:198–210. doi:10.1016/j.gendis.2016.04.007
12. Adamson C, Kanu OO, Mehta AI et al (2009) Glioblastoma multiforme: A review of where we have been and where we are going. Expert Opin Investig Drugs 18:1061–1083. doi:10.1517/13543780903052764
13. Nair MK, Varghese C, Swaminathan R (2015) Cancer: Current Scenario, Intervention Strategies and Projections for. NCMH Background Papers Burden of Disease in India.. http://www.sciepub.com/reference/234114. Accessed 20 Dec 2020
14. Acharya MM, Green KN, Allen BD et al (2016) Elimination of microglia improves cognitive function following cranial irradiation. Sci Rep. doi:10.1038/srep31545
15. Jalali R, Datta D (2008) Prospective analysis of incidence of central nervous tumors presenting in a tertiary cancer hospital from India. J Neurooncol 87:111–114. doi:10.1007/s11060-007-9487-z
16. TAMIMI AF, JUWEID M (2017) Epidemiology and Outcome of Glioblastoma. In: Glioblastoma. Codon Publications, pp 143–153
17. Sun T, Plutynski A, Ward S et al (2015) An integrative view on sex differences in brain tumors. Cell Mol Life Sci 72:3323–3342. doi:10.1007/s00018-015-1930-2
18. Chay CH, Cooper CR, Gendernalik JD et al (2002) A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 60:760–765. doi:10.1016/S0090-4295(02)01969-6
19. Wang G, Zhao D, Spring DJ et al (2018) Genetics and biology of prostate cancer. Genes Dev 32:1105–1140. doi:10.1101/gad.315739.118
20. Morris GJ, Naidu S, Topham AK et al (2007) Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients. Cancer 110:876–884. doi:10.1002/cncr.22836
21. Clinical significance of serum protease activated receptor1 levels in patients with lung cancer - PubMed. https://pubmed.ncbi.nlm.nih.gov/26875892/. Accessed 20 Dec 2020
22. Lin JJ, Shaw AT (2016) Resisting Resistance: Targeted Therapies in Lung Cancer. Trends in Cancer 2:350–364. doi:10.1016/j.trecan.2016.05.010
23. Proteinase-activated receptors - PubMed. https://pubmed.ncbi.nlm.nih.gov/11356985/. Accessed 20 Dec 2020
24. Heuberger DM, Schuepbach RA (2019) Protease-activated receptors (PARs): Mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thromb J 17:4. doi:10.1186/s12959-019-0194-8
25. Even-Ram SC, Maoz M, Pokroy E et al (2001) Tumor Cell Invasion Is Promoted by Activation of Protease Activated Receptor-1 in Cooperation with the αvβ5 Integrin. J Biol Chem 276:10952–10962. doi:10.1074/jbc.M007027200
26. Kempkes C, Rattenholl A, Buddenkotte J et al (2012) Proteinase-activated receptors 1 and 2 regulate invasive behavior of human melanoma cells via activation of protein kinase D1. J Invest Dermatol 132:375–384. doi:10.1038/jid.2011.314
27. Arora P, Ricks TK, Trejo JA (2007) Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J Cell Sci 120:921–928. doi:10.1242/jcs.03409
28. Auvergne R, Wu C, Connell A et al (2016) PAR1 inhibition suppresses the self-renewal and growth of A2B5-defined glioma progenitor cells and their derived gliomas in vivo. Oncogene 35:3817–3828. doi:10.1038/onc.2015.452
29. Hetherington S, Turgeon V (2019) Relative expression of protease-activated receptor 1 (PAR-1) mRNA in rat Schwann cells remains stable following PAR-1 activation. Bios 90(4):208–217. doi:10.2307/26867866
30. Xie Q, Bao X, Chen ZH et al (2016) Role of protease-activated receptor-1 in glioma growth. In: Acta Neurochir. Suppl. Springer-Verlag Wien, pp 355–360
31. Wojtukiewicz MZ, Hempel D, Sierko E et al (2015) Protease-activated receptors (PARs)—biology and role in cancer invasion and metastasis. Cancer Metastasis Rev 34:775–796. doi:10.1007/s10555-015-9599-4

32. Liu X, Yu J, Song S et al (2017) Protease-activated receptor-1 (PAR-1): A promising molecular target for cancer. Oncotarget 8:107334–107345. doi:10.18632/oncotarget.21015

33. Zhu Z, Reiser G (2014) Signaling mechanism of protease activated receptor 1-induced proliferation of astrocytes: Stabilization of hypoxia inducible factor-1α triggers glucose metabolism and accumulation of cyclin D1. Neurochem Int 79:20–32. doi:10.1016/j.neuint.2014.09.010

34. Deschepper CF, Bigornia V, Berens ME et al (1991) Production of thrombin and antithrombin III by brain and astroglial cell cultures. Mol Brain Res 11:355–358. doi:10.1016/0169-328X(91)90045-Y

35. Ubl JJ, Vöhringer C, Reiser G (1998) Co-existence of two types of [Ca2+]i-inducing protease-activated receptors (PAR-1 and PAR-2) in rat astrocytes and C6 glioma cells. Neuroscience 86:597–609. doi:10.1016/S0306-4522(97)00686-6

36. Cheema TA, Ward CE, Fisher SK (2005) Subnanomolar concentrations of thrombin enhance the volume-sensitive efflux of taurine from human 1321N1 astrocytoma cells. J Pharmacol Exp Ther 315:755–763. doi:10.1124/jpet.105.090787

37. Fan Y, Zhang W, Mulholland M (2005) Thrombin and PAR-1-AP increase proinflammatory cytokine expression in C6 cells. J Surg Res 129:196–201. doi:10.1016/j.jss.2005.07.041

38. Morrow DA, Braunwald E, Bonaca MP et al (2012) Vorapaxar in the Secondary Prevention of Atherothrombotic Events. N Engl J Med 366:1404–1413. doi:10.1056/nejmoa1200933

39. Hua Y, Vickers TA, Okunola HL et al (2008) Antisense Masking of an hnRNP A1/A2 Intrinsic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice. Am J Hum Genet 82:834–848. doi:10.1016/j.ajhg.2008.01.014

40. Chapman J (2013) Coagulation in inflammatory diseases of the central nervous system. Semin Thromb Hemost 39:876–880. doi:10.1055/s-0033-1357482

41. Itsekson-Hayosh Z, Shavit-Stein E, Last D et al (2015) Thrombin Activity and Thrombin Receptor in Rat Glioblastoma Model: Possible Markers and Targets for Intervention? J Mol Neurosci 56:644–651. doi:10.1007/s12031-015-0512-y

42. Pearson JRD, Regad T (2017) Targeting cellular pathways in glioblastoma multiforme. Signal Transduct Target Ther. doi:10.1038/sigtrans.2017.40

43. Kuhn SA, Martin M, Brodhun M et al (2014) Overexpression of protease-activated receptor type 1 (PAR-1) in glioblastoma multiforme WHO IV cells and blood vessels revealed by NCAM-assisted glioblastoma border labeling. Neurol Res 36:709–721. doi:10.1179/1743132813Y.0000000303

44. Shavit-Stein E, Sheinberg E, Golderman V et al (2018) A Novel Compound Targeting Protease Receptor 1 Activators for the Treatment of Glioblastoma. Front Neurol 9:1087. doi:10.3389/fneur.2018.01087

45. Bowden SG, Gill BJA, Englander ZK et al (2018) Local glioma cells are associated with vascular dysregulation. Am J Neuroradiol 39:507–514. doi:10.3174/ajnr.A5526
46. Malmström A, Åkesson L, Asklund T et al (2018) P01.151 Gender differences in glioma - findings from the Swedish National Quality Registry for Primary Brain Tumors. Neuro Oncol 20:iii267–iii267. doi:10.1093/neuonc/noy139.193